Navigation Links
Differing reactions to anti clotting drugs may be due to genetic variation.,,

People who take anti clotting drugs like warfarin may react differently to the drug because of their genetic makeup.//

A sizable population of the world takes anti clotting medications in the event of heart attacks, stroke or major surgery to check harmful clotting of blood. However the difference in the reactions to the drugs have foxed the physicians for long and made it difficult to standardize the proper dosage of the drug. A little change in dose often may result in more reactions to blood flow.

Researchers of University of Washington in Seattle had discovered the variations in a gene that alters the way people respond to blood clotting medications. The gene encodes the CYP2C9 enzyme that metabolizes the anti clot drug and thus accounts for almost 10% variations of the reactions to the drug warfarin.

When are patients are tested for variations in reactions to medications, the tests mostly concentrate on the sex, age, weight and medical history of the patients. It may take months of visits to the physicians to find out the right dose for the patient even then. Genetic variations are often not considered here. The new research will emphasize the study of people’s reaction to medications and their genetic coding, also called pharmacogenetics.

Reference: National Institutes of Health, news release, June 2005
'"/>




Page: 1

Related medicine news :

1. Differing Ideas on Management of Alzheimer’s diseas
2. ZYBAN, The smoking cessation drug marked for its adverse reactions
3. Lupin flour may cause peanut allergy like reactions
4. Arsenic poisoning reactions can be traced to genes
5. stents Result in allergic reactions
6. Aspirin surpasses Modern Anti-clotting Drugs
7. Enduring anti-clotting treatment avails heart patients
8. Treatment over a longer period for blood clotting
9. Gum disease may be caused by blood clotting gene
10. Anlene brand of milk products will carry warnings about blood-clotting risks
11. Bivalirudin, a new anti-clotting drug may be a safer option for treatment of acute coronary conditions
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson ... offers insurance and financial preparation services, is providing an update on a charitable ... , Rock City Rescue is a locally recognized nonprofit that provides shelter and ...
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate professor Janice ... of cardiovascular diseases during the 15th Annual Women’s Health Conference. The SIU ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... ... 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought ... This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at ... towards children of all ages; it is a non-competitive, non-timed event, which is all ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Oct. 2, 2017 Halo Labs announces the European launch ... called the HORIZON at MIBio 2017 in Cambridge, U.K ... visible particulate matter in biopharmaceutical samples with unprecedented speed and sensitivity ... novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/27/2017)... 27, 2017  Commended for their devotion to personalized service, ... as number one in the South Florida Business Journal,s 50 ... 5000 yearly list, the national specialty pharmacy has found its ... will soon be honored by SFBJ as the 2017 ... Set to receive his award in October, Bardisa said ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
Breaking Medicine Technology: